Novartis Ag (NVS) Interest Coverage Ratio (2009 - 2026)
Novartis Ag (NVS) posted Interest Coverage Ratio of 10.28 for Q2 2026, down 38.91% sequentially from 16.83 in Q2 2025, and down 38.91% YoY from 16.83 in Q2 2025.
Novartis Ag (NVS) Interest Coverage Ratio (2009 - 2026) Analysis & Trends
Novartis Ag has reported Interest Coverage Ratio for 18 years, with the latest figure at 10.28 in Q2 2026.
- Quarterly Interest Coverage Ratio fell 38.91% year-over-year to 10.28 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 90.67 (down 102.3% YoY) and the FY2025 annual result came in at 15.42, up 6.68% from the prior year.
- Interest Coverage Ratio fell to 10.28 in Q2 2026 per NVS's latest filing, from 16.83 in the prior quarter.
- Over five years, Interest Coverage Ratio peaked at 16.83 in Q2 2025 and troughed at 169157.82 in Q1 2022.
- A 5-year average of 17659.25 and a median of 11.03 in 2022 frame the typical range for Interest Coverage Ratio.
- The sharpest annual moves came in 2023 and 2024: Interest Coverage Ratio surged 213.61% in 2023, then tumbled 373.66% in 2024.
- Over 5 years, Interest Coverage Ratio stood at 50.93 in 2022, then jumped by 83.31% to 8.5 in 2023, then sank by 373.66% to 40.28 in 2024, then soared by 141.79% to 16.83 in 2025, then slumped by 38.91% to 10.28 in 2026.
- According to Business Quant data, Interest Coverage Ratio over the past three periods registered 10.28, 16.83, and 40.28 for Q2 2026, Q2 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 25.41 |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | - |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 10.28 |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 7.27 |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 5.22 |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | -42.08 |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | - |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | -2.64 |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | -50.26 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 10.28 |
| Jun 30, 2025 | 16.83 |
| Dec 31, 2024 | -40.28 |
| Jun 30, 2024 | -15.74 |
| Dec 31, 2023 | -8.50 |
| Jun 30, 2023 | 12.53 |
| Mar 31, 2023 | -25,003.81 |
| Dec 31, 2022 | -50.93 |
| Sep 30, 2022 | -3.27 |
| Jun 30, 2022 | -11.03 |
| Mar 31, 2022 | -169,157.82 |
| Dec 31, 2021 | -29.90 |
| Sep 30, 2021 | -3.59 |
| Jun 30, 2021 | -17.31 |
| Mar 31, 2021 | -69,310.48 |
| Dec 31, 2020 | -24.80 |
| Sep 30, 2020 | -86,127.77 |
| Jun 30, 2020 | -10.36 |
| Mar 31, 2020 | 0.19 |
| Jun 30, 2019 | -11.14 |